. Dec 2024Oct 2024Aug 2024Jun 2024Apr 2024Feb 20242.53.03.54.04.5 End of interactive chart. EPS - PE - Div Rate - Yield - Short Interest - Market Cap - Volume - Prev. Close -Sorry, this data cannot be displayed at the moment. MAYNF News...
Market Cap - Volume - Prev. Close - IPHA News Innate Pharma S.A. (IPHA) Q3 2024 Earnings Call Transcript See All News » Ratings Summary Sorry, this data cannot be displayed at the moment. Factor Grades Sorry, this data cannot be displayed at the moment. ...
displacing longtime stalwarts with unprecedented sales. But, as 2023 featured major patent expirations, the rise of weight loss drugs and other new dynamics, the year’s ranking of the top 20 drugs by global sales featured its fair share of surprises...
But, as 2023 featured major patent expirations, the rise of weight loss drugs and other new dynamics, the year’s ranking of the top 20 drugs by global sales featured its fair share of surprises. Merck’s oncology king Keytruda rose to the top last year, adding yet another feather in ...
Quant Ranking ? Sector 网页链接{Health Care} Industry Biotechnology Ranked Overall 网页链接{3463 out of 4450} Ranked in Sector 网页链接{733 out of 1037} Ranked in Industry 网页链接{337 out of 496} 网页链接{Quant Ratings Beat The Market »} ...
Celltrion HealthCare has become the largest company in KOSDAQ with the market cap reaching 11.26 trillion won after Celltrion moved to the main bourse KOSPI. SillaJen ranks second with 5.7 trillion won, followed by Medytox’s fourth-ranking with 3.7 trillion won. ViroMed is at the sixth with 3....
quant ranking cocp analysis is cocrystal beating the dead hepatitis c horse? bz equity research tue, aug. 14, 2018 26 comments how cocrystal can open the door to a new era in genetic medicine with crispr austrolib mon, apr. 04, 2016 25 comments insiderinsights.com daily round up 3/17/...
Market Cap Volume Prev. Close BBIO Analysis BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats BBIO News BridgeBio Pharma GAAP EPS of -$0.86 beats by $0.09, revenue of $2.73M misses by $0.65M See All News » ...
top of the pharma industry's sales charts, displacing longtime stalwarts with unprecedented sales. But, as 2023 featured major patent expirations, the rise of weight loss drugs and other new dynamics, the year’s ranking of the top 20 drugs by global sales featured its fair share of ...
But, as 2023 featured major patent expirations, the rise of weight loss drugs and other new dynamics, the year’s ranking of the top 20 drugs by global sales featured its fair share of surprises. Merck’s oncology king Keytruda rose to the top last year, adding yet another feather in ...